Optimising the duration of adjuvant trastuzumab in early breast cancer in the UK
AuthorsEarl, H. M.
Abraham, J. E.
Cameron, D. A.
Wardley, Andrew M
AffiliationDepartment of Oncology, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK;
MetadataShow full item record
CitationEarl HM, Hiller L, Dunn J, Macpherson I, Rea D, Hughes-Davies L, et al. Optimising the Duration of Adjuvant Trastuzumab in Early Breast Cancer in the UK. Clinical Oncology. 2020.
- Updated cost-effectiveness analysis of trastuzumab for early breast cancer: a UK perspective considering duration of benefit, long-term toxicity and pattern of recurrence.
- Authors: Hall PS, Hulme C, McCabe C, Oluboyede Y, Round J, Cameron DA
- Issue date: 2011 May
- One year versus a shorter duration of adjuvant trastuzumab for HER2-positive early breast cancer: a systematic review and meta-analysis.
- Authors: Inno A, Barni S, Ghidini A, Zaniboni A, Petrelli F
- Issue date: 2019 Jan
- Six versus 12 months' adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT.
- Authors: Earl H, Hiller L, Vallier AL, Loi S, McAdam K, Hughes-Davies L, Rea D, Howe D, Raynes K, Higgins HB, Wilcox M, Plummer C, Mahler-Araujo B, Provenzano E, Chhabra A, Gasson S, Balmer C, Abraham JE, Caldas C, Hall P, Shinkins B, McCabe C, Hulme C, Miles D, Wardley AM, Cameron DA, Dunn JA
- Issue date: 2020 Aug
- 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial.
- Authors: Earl HM, Hiller L, Vallier AL, Loi S, McAdam K, Hughes-Davies L, Harnett AN, Ah-See ML, Simcock R, Rea D, Raj S, Woodings P, Harries M, Howe D, Raynes K, Higgins HB, Wilcox M, Plummer C, Mansi J, Gounaris I, Mahler-Araujo B, Provenzano E, Chhabra A, Abraham JE, Caldas C, Hall PS, McCabe C, Hulme C, Miles D, Wardley AM, Cameron DA, Dunn JA, PERSEPHONE Steering Committee and Trial Investigators.
- Issue date: 2019 Jun 29
- Risk of Congestive Heart Failure in Early Breast Cancer Patients Undergoing Adjuvant Treatment With Trastuzumab: A Meta-Analysis.
- Authors: Long HD, Lin YE, Zhang JJ, Zhong WZ, Zheng RN
- Issue date: 2016 May